Physician profile
Leon P Mclean
NPI 1457495806
$170,776.92
in general payments reported to CMS, 2019-2025
16 companies · $45K in 2025
The $45K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,509 · 2021: $16K · 2022: $36K · 2023: $35K · 2024: $24K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $10K · Consulting Fee: $7,560 · Food and Beverage: $4,958 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,879.36 |
| Travel and Lodging | $10,273.12 |
| Consulting Fee | $7,560.00 |
| Food and Beverage | $4,957.51 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99,076.11 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $46,153.49 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $17,277.78 | 2022-2025 | Tremfya, Stelara |
| Pfizer INC. | $5,797.49 | 2024-2025 | |
| Celgene Corporation | $1,461.16 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $389.39 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.84 | 2019-2025 | Xifaxan, Trulance |
| Conmed Corporation | $158.36 | 2019 | |
| Gilead Sciences, INC. | $81.29 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $36.96 | 2023 | Linzess |
| Celltrion USA INC. | $32.71 | 2024-2025 | Vegzelma, Zymfentra |
| Genzyme Corporation | $24.90 | 2023 | |
| Merck Sharp & Dohme LLC | $22.26 | 2022 | |
| Qol Medical, LLC | $21.09 | 2024 | Sucraid |
| Alfasigma USA, INC. | $17.49 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $14.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Mclean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.